Conjunctival inflammation in dupilumab-treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study

Note: Funding Information: D.S. Bakker reports personal fees from Sanofi/Regeneron, personal fees from Leo Pharma, outside the submitted work. C.M. van Luijk reports personal fees from Sanofi Europe and Santen Europe, outside the submitted work. Dr. de Bruin‐Weller reports grants and other from Sanofi‐Genzyme, grants and other from Regeneron, grants and other from AbbVie, other from Arena, other from Almirall, grants and other from Eli‐Lilly, other from Galderma, other from Janssen, grants and other from Leo Pharma, other from Pfizer, outside the submitted work. Dr. Thijs reports personal fees from Sanofi/Regeneron and Leo Pharma, outside the submitted work. Dr. Vercoulen reports grants from NWO Gravitation 024.001.028 cancergenomicscenter.nl, during the conduct of the study; grants from WKZ fund research grant, grants from TKI‐Health Holland grant, grants and non‐financial support from TigaTx B.V., grants from Vrienden van het UMC Utrecht, non‐financial support from Life Science editors parental leave grant, outside the submitted work. Dr. van Wijk reports grants from Investigator initiated studies Regeneron and Leo Pharma, outside the submitted work. All other authors have nothing to disclose.